MarketVIEW: *Chlamydia trachomatis* vaccines (CAT: VAMV003)

**Product Name**: MarketVIEW: *Chlamydia trachomatis* vaccines

**Description**: Comprehensive vaccine opportunity assessment

**Contents**: Executive presentation + MS Excel model

**Therapeutic Area**: Adolescent vaccines

**Publication date**: June 2012

**Catalogue No**: VAMV003

**Background**

After the global success of new HPV vaccines focused on sexually transmitted infections (STDs), vaccine manufacturers are considering other high-burden infections in the adolescent group, especially *Chlamydia trachomatis* (CT). CT is a major cause of serious reproductive complications in the female with outcomes such as pelvic inflammatory disease (PID) and ectopic pregnancies. Although diagnosed infections with *Chlamydia trachomatis* are curable with antibiotic therapy, the vast majority infections are “silent” and unrecognized. Even after treatment re-infection rates of CT remain high with little chance of eradication within the population.

This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of a prophylatic *Chlamydia* vaccine across the major Western and emerging markets (BRIC-M). The model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, pricing and penetration estimates. LO/BASE/HI forecast scenarios are included relative to Gardasil adoption as a case study. The impact of country dependent National Immunization Programs and funded "catch-up" campaigns is also studied.
Methodology

VacZine Analytics has closely monitored all significant source material pertaining to Chlamydia trachomatis epidemiology/vaccines and consulted with global experts regarding their predictions of vaccine deployment. Secondary source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by VacZine Analytics in the adolescent field has also been utilised.

PRODUCT CONTENTS:
Published June 2012 (CAT No: VAMV003)
****This product is composed of a model and summary presentation

Contents – Summary presentation (MS PowerPoint based)

Executive Summary
Commercial model – key outputs
Total available demand: Chlamydia vaccine, global, (000s doses)
Total available demand: Chlamydia vaccine, high-income markets, (000s doses)
Total available demand: Chlamydia vaccine, emerging markets, (000s doses)
Total available market: Chlamydia vaccine, global, ($ 000s)
Total available market: Chlamydia vaccine, by market, ($ 000s)
Total available market: Chlamydia vaccine, price sensitivity analysis, ($ 000s)
Chlamydia vaccine: country volume analysis, 2025 (000s doses)
Chlamydia vaccine: country value analysis, 2025 ($ 000s)
The role of a CT vaccine
Commercial model – key assumptions
Pricing
Model forecast comparisons: June 2011 v current
Chlamydia vaccine opportunity: target product profile
Overall commercial model assumptions per country
Chlamydia trachomatis: brief background
Clinical features
Chlamydia trachomatis: natural history of infection
Chlamydia trachomatis: global incidence
Chlamydia trachomatis: global prevalence
US epidemiology
UK epidemiology
Reasons for increasing incidence
Potential impact of a CT vaccine
Competitor landscape: overview
Competitive environment: major players
Chlamydia trachomatis vaccine – HPV, a relevant case study?
HPV vaccines: analysis of country uptake
Bibliography
Disclaimer
About VacZine Analytics

PAGES: ~57 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form
Contents – Vaccine demand model (MS Excel-based)

Title Sheet
Scenario definition
Value Scenario Analysis
Value Summary (Western)
Volume Summary (Western)
Value Summary (Emerging)
Volume Summary (Emerging)
Charts – volume (Western)
Charts – value (Western)
Charts – value/volume (Western)
Females (Western) ➔
US (13 yrs/ 14 - 18 yrs)
Canada
UK
France
Germany
Italy
Spain
Other EU
Australia
Japan
Females (Emerging) ➔
Brazil
Russia
India
China
Mexico
Population database
Competition – IP landscape
Assumptions – major markets
Back page
About VacZine Analytics
Disclaimer

WORKSHEETS: ~65
PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- USD $8995.00/ GBP £5800.00# (Region license)*

*A region is North America, Europe or ROW
For orders in the UK, VAT at 20 % will be added to final invoice total
#Indicative – prevailing rate to be applied on date of transaction

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased on-line. Please review the TERMS and CONDITIONS of purchase.
Bibliography

10. Vaccines and Related Biological Products Advisory Committee May 18, 2006. GARDASIL Quadrivalent HPV (Types 6, 11, 16, 18) L1 VLP Vaccine, Merck Research Laboratories.
22.
23. Quadrivalent Human Papilloma Virus Vaccine. MMWR Recommendations and Reports. March 23 2007 /56 (RR02);1 -24
TERMS and CONDITIONS:
VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.
3. Cancellation policy. The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. Cancellation rights: For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client’s cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master TERMS and CONDITIONS available upon request.

VacZine Analytics
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com
About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009